{"result": "(\"entity\"<|>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS<|>ORGANIZATION<|>The American Association of Clinical Endocrinologists is a professional organization that provides guidelines for the medical care of patients with obesity.)\n##\n(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is a professional organization that develops clinical practice guidelines for the management of obesity.)\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a peer-reviewed medical journal that publishes clinical trials and studies related to various health issues, including obesity and cardiovascular events.)\n##\n(\"entity\"<|>LIRAGLUTIDE<|>EVENT<|>Liraglutide is a human glucagon-like peptide-1 analog used in the treatment of obesity and type 2 diabetes.)\n##\n(\"entity\"<|>PHENTERMINE<|>EVENT<|>Phentermine is a medication used for weight loss, often in combination with other drugs like topiramate.)\n##\n(\"entity\"<|>TOPIRAMATE<|>EVENT<|>Topiramate is a medication that is used in combination with phentermine for weight management in obese patients.)\n##\n(\"entity\"<|>CONQUER<|>EVENT<|>CONQUER is a randomized, placebo-controlled trial studying the effects of phentermine and topiramate on weight and associated comorbidities.)\n##\n(\"entity\"<|>SEQUEL<|>EVENT<|>SEQUEL is a randomized, placebo-controlled, phase 3 extension study on the long-term effects of phentermine/topiramate in obese adults.)\n##\n(\"entity\"<|>XENDOS<|>EVENT<|>XENDOS is a study focused on the prevention of diabetes in obese subjects using the medication Xenical.)\n##\n(\"entity\"<|>BMJ<|>ORGANIZATION<|>BMJ is a peer-reviewed medical journal that publishes research and reviews on various medical topics, including obesity treatment.)\n##\n(\"relationship\"<|>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS<|>ENDOCRINE SOCIETY<|>Both organizations provide clinical practice guidelines for the management of obesity<|>7)\n##\n(\"relationship\"<|>ENDOCRINE SOCIETY<|>JAMA<|>The Endocrine Society's guidelines are often published in JAMA, which disseminates clinical research<|>6)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>SEQUEL<|>Liraglutide is studied in the SEQUEL trial for its effects on weight management<|>8)\n##\n(\"relationship\"<|>PHENTERMINE<|>CONQUER<|>Phentermine is a key medication studied in the CONQUER trial for weight loss<|>9)\n##\n(\"relationship\"<|>TOPIRAMATE<|>CONQUER<|>Topiramate is used in combination with phentermine in the CONQUER trial for weight management<|>9)\n##\n(\"relationship\"<|>XENDOS<|>BMJ<|>The XENDOS study is published in BMJ, which reviews obesity treatment studies<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Mechanick JI, Brett EM, Garber AJ,\n       C, Rubio-Herrera MA. Update on pharmacology of                               Hurley DL, Jastreboff AM, et al. American Asso-\n       obesity: Benefits and risks. Nutr Hosp 2013; 28 Sup-                         ciation of Clinical Endocrinologists and Ameri-\n       pl 5:121-7.                                                                  can   College     of  Endocrinology        comprehensive\n   5.  Apovian CM, Aronne L J, Bessesen DH, McDonnell                               clinical practice guidelines for medical care of\n       ME, Murad MH, Pagotto U, et al. Pharmacological                              patients with obesity.Endocr Pract. 2016;22 Su-\n       management of obesity: an endocrine Society clini-                           ppl 3:1-203.\n       cal  practice    guideline.    J  Clin  Endocrinol     Metab.          11.   Allison DB, Gadde KM, Garvey WT, Peterson CA,\n       2015; 100: 342-62.                                                           Schwiers ML, Najarian T, Tam PY, Troupin B, Day\n---\n 140      BLOQUE: ALTERACIONES DE LA ENERGÍA\n\n\n\n      WW. Controlled-release phentermine/ topiramate                        Major Adverse Cardiovascular Events in Overwei-\n      in severely obese adults: a randomized controlled                     ght and Obese Patients With Cardiovascular Risk\n      trial (EQUIP). Obesity. 2012; 20:330-42.                              Factors: A Randomized Clinical Trial. JAMA. 2016;\n12.   Gadde KM, Allison DB, Ryan DH, Peterson CA,                           315:990-1004.\n      Troupin     B,  Schwiers     ML,    Day   WW.      Effects   of  22.  Drucker DJ, Nauck MA. The incretin system: gluca-\n      low-dose,     controlled-release,       phentermine       plus        gon-like peptide-1 receptor agonists and dipeptid-\n      topiramate combination on weight and associated                       yl peptidase-4 inhibitors in type 2 diabetes. Lancet.\n      comorbidities      in  overweight       and   obese     adults        2006; 368: 1696-1705.\n      (CONQUER):        a   randomised,       placebocontrolled,       23.  Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S,\n      phase 3 trial. Lancet. 2011; 377:1341-52.                             Raskin P, et al. Efficacy and safety of the human\n13.   Garvey WT, Ryan DH, Look M, Gadde KM, Allison                         glucagon-like peptide-1 analog liraglutide in com-\n      DB, Peterson CA, Schwiers M, Day WW, Bowden                           bination with metformin and thiazolidinedione in\n      CH. Two-year sustained weight loss and metabolic                      patients with type 2 diabetes (LEAD-4 Met+TZD).\n      benefits with controlled-release phentermine/topi-                    Diabetes Care. 2009; 32:1224-30.\n      ramate in obese and overweight adults (SEQUEL):                  24.  Vilsbøll T, Christensen M, Junker AE, Knop FK,\n      a randomized, placebo-controlled, phase 3 exten-                      Gluud LL. Effects of glucagon-like peptide-1 re-\n      sion study. Am J Clin Nutr. 2012; 95:297-308.                         ceptor agonists on weight loss: systematic review\n14.   Rucker D, Padwal R, Li SK, Curioni C, Lau DCW.                        and meta-analyses of randomised controlled trials.\n      Long    term     pharmacotherapy          for  obesity     and        BMJ. 2012; 344:d7771.\n      overweight: updated meta-analysis. BMJ. 2007;                    25.  Astrup A, Carraro R, Finer N, Harper A, Kunesova\n      335 (7631): 1194-9.                                                   M, Lean MEJ, et al. Safety, tolerability and sustai-\n15.   Torgerson JS, Hauptman J, Boldrin MN, Sjöström                        ned weight loss over 2 years with the once-daily\n      L. Xenical in the prevention of diabetes in obese                     human GLP-1 analog, liraglutide. Int J Obes (Lond)\n      subjects (XENDOS) study. Diabetes Care. 2004;                         2012; 36: 843-54.\n      27:155-61.                                                       26.  Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Hal-\n16.   Anderson JW, Greenway FL, Fujioka K, Gadde KM,                        pern A, Krempf M. et al. A Randomized, Contro-\n      McKenney J, O’Neil PM. Bupropion SR enhances                          lled Trial of 3.0 mg of Liraglutide in Weight Mana-\n      weight     loss:   a   48-week      double-blind,       place-        gement. New Engl J Med. 2015; 373:11-22.\n      bo-controlled trial. Obes Res 2002; 10: 633-641.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}